ACE2 improves right ventricular function in a pressure overload model

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Johnson, Jennifer A ^a   West, James ^a   Maynard, Karen B ^a   Hemnes, Anna R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA1; CONNEXIN 37; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; DIPEPTIDYL CARBOXYPEPTIDASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMMUNICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART PROTECTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; DIASTOLE; DISEASE MODEL; FIBROSIS; HEMODYNAMICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROVASCULATURE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSURE; SIGNAL TRANSDUCTION; SYSTOLE;

MUS;

ANIMALS; DIASTOLE; DISEASE MODELS, ANIMAL; FIBROSIS; HEMODYNAMICS; HUMANS; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICROVESSELS; PEPTIDYL-DIPEPTIDASE A; PRESSURE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SYSTOLE; VENTRICULAR FUNCTION, RIGHT;

EID: 79958734872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020828     Document Type: Article

References (45)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-54.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
3. Polak JF, Holman BL, Wynne J, Colucci WS, (1983) Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol 2: 217-224.
4. Ritchie M, Waggoner AD, Davila-Roman VG, Barzilai B, Trulock EP, et al. (1993) Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantation. J Am Coll Cardiol 22: 1170-1174.
5. Reesink HJ, Marcus JT, Tulevski II, Jamieson S, Kloek JJ, et al. (2007) Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 133: 58-64.
6. Winter MM, Bouma BJ, Groenink M, Konings TC, Tijssen JG, et al. (2009) Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure. Heart 95: 960-963.
7. Schmieder RE, Martus P, Klingbeil A, (1996) Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275: 1507-1513.
8. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677.
9. SOLVD I, (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302.
10. Harmer D, Gilbert M, Borman R, Clark KL, (2002) Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532: 107-110.
11. Gallagher PE, Ferrario CM, Tallant EA, (2008) Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 295: H2373-2379.
12. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, et al. (2008) Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326.
13. Santos RA, Ferreira AJ, (2007) Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 16: 122-128.
14. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, et al. (2007) Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-742.
15. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, et al. (2007) ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113: 357-364.
16. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, et al. (2008) Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718.
17. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, et al. (2009) Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2: 446-455.
18. Zhong J, Basu R, Guo D, Chow FL, Byrns S, et al. (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122: 717-728, 718 p following 728.
19. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, et al. (2008) Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52: 750-754.
20. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, et al. (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15: 565-571.
21. Hemnes AR, Champion HC, (2008) Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract Suppl pp. 11-19.
22. Kelly RG, Brown NA, Buckingham ME, (2001) The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell 1: 435-440.
23. Waldo KL, Kumiski DH, Wallis KT, Stadt HA, Hutson MR, et al. (2001) Conotruncal myocardium arises from a secondary heart field. Development 128: 3179-3188.
24. Mjaatvedt CH, Nakaoka T, Moreno-Rodriguez R, Norris RA, Kern MJ, et al. (2001) The outflow tract of the heart is recruited from a novel heart-forming field. Dev Biol 238: 97-109.
25. Dyer LA, Kirby ML, (2009) The role of secondary heart field in cardiac development. Dev Biol 336: 137-144.
26. Lovren F, Pan Y, Quan A, Teoh H, Wang G, et al. (2008) Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 295: H1377-1384.
27. Haefliger JA, Polikar R, Schnyder G, Burdet M, Sutter E, et al. (2000) Connexin37 in normal and pathological development of mouse heart and great arteries. Dev Dyn 218: 331-344.
28. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ, (1997) Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273: H1769-1774.
29. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, et al. (2001) Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 86: 203-214.
30. Miyazaki M, Takai S, Jin D, Muramatsu M, (2006) Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 112: 668-676.
31. Doggrell SA, Wanstall JC, (2004) Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 61: 653-662.
32. Kaartinen M, Penttila A, Kovanen PT, (1994) Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 14: 966-972.
33. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, et al. (2003) A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-a zetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305: 17-23.
34. Batlle M, Roig E, Perez-Villa F, Lario S, Cejudo-Martin P, et al. (2006) Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J Heart Lung Transplant 25: 1117-1125.
35. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828.
36. Giani JF, Gironacci MM, Munoz MC, Turyn D, Dominici FP, (2008) Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol 93: 570-578.
37. Giani JF, Gironacci MM, Munoz MC, Pena C, Turyn D, et al. (2007) Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am J Physiol Heart Circ Physiol 293: H1154-1163.
38. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, et al. (2008) Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52: 542-548.
39. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, et al. (2009) Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 179: 1048-1054.
40. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, et al. (2009) Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54: 365-371.
41. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, et al. (2010) The ACE2/Ang-(1-7)/Mas Axis Confers Cardiopulmonary Protection against Lung Fibrosis and Pulmonary Hypertension. Am J Respir Crit Care Med.
42. Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, et al. (2003) Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 35: 1043-1053.
43. De Mello WC, Ferrario CM, Jessup JA, (2007) Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst 8: 74-80.
44. Syed F, Diwan A, Hahn HS, (2005) Murine echocardiography: a practical approach for phenotyping genetically manipulated and surgically modeled mice. J Am Soc Echocardiogr 18: 982-990.
45. Collins KA, Korcarz CE, Lang RM, (2003) Use of echocardiography for the phenotypic assessment of genetically altered mice. Physiol Genomics 13: 227-239.